CJC-1295 with DAC

PeptideXpo buyer fit

Overview

CJC-1295 with DAC is the long-acting variant of the Modified GRF 1-29 family, carrying a maleimido-propionyl group at Lys30 that allows covalent reaction with Cys34 of serum albumin in vivo, the Drug Affinity Complex (DAC) mechanism. The albumin conjugation dramatically extends plasma half-life from roughly 30 minutes (no-DAC) to approximately 6-8 days, supporting once-weekly dosing schedules in research and compounding contexts. PeptideXpo supplies CJC-1295 with DAC as the lyophilized acetate at ≥99.0% HPLC purity. The DAC variant requires more demanding analytical confirmation than the no-DAC form because the maleimido modification must be intact at the labelled position, partially hydrolyzed maleimide loses the in vivo albumin-binding activity even though it passes the standard HPLC purity gate at equivalent retention time. The release packet covers peak-integration HPLC plus ESI mass spec confirming the modified mass; intact-maleimide confirmation by reactivity assay against a reference thiol is available when required by a written analytical scope. The DAC form's pharmacokinetic profile makes it more appropriate for sustained-elevation GH research and for compounding contexts where weekly dosing matters, while the no-DAC form is preferred for pulse-pharmacology research.

Who buys this, and why

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS

863288-34-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 5.8-8.1 days

MOQ

On request

Lead time

10–18 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion (acetate vs TFA)
• Sterile-fill release pack (sterility, CCI, fill-weight)
• Bacterial endotoxin (LAL, USP <85>)
• Stability data on request
• SDS / MSDS

Regulatory note

Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
4. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.

Frequently asked questions